688276 百克生物
已收盘 12-05 15:00:01
资讯
新帖
简况
生长激素难助业绩长高!昔日“东北药茅”欲借港股翻盘?
投资时报 · 11-24
生长激素难助业绩长高!昔日“东北药茅”欲借港股翻盘?
11月21日百克生物跌5.81%,金鹰鑫瑞混合A基金重仓该股
证券之星 · 11-21
11月21日百克生物跌5.81%,金鹰鑫瑞混合A基金重仓该股
每周股票复盘:百克生物(688276)成人百白破疫苗获临床试验批准
证券之星 · 11-16
每周股票复盘:百克生物(688276)成人百白破疫苗获临床试验批准
百克生物(688276)披露选举第六届董事会职工代表董事,11月14日股价上涨1.93%
证券之星 · 11-14
百克生物(688276)披露选举第六届董事会职工代表董事,11月14日股价上涨1.93%
百克生物(688276.SH):吸附无细胞百(二组分)白破联合疫苗(成人及青少年用)临床试验申请获得批准
智通财经 · 11-12
百克生物(688276.SH):吸附无细胞百(二组分)白破联合疫苗(成人及青少年用)临床试验申请获得批准
每周股票复盘:百克生物(688276)前三季度净亏损1.58亿元
证券之星 · 11-09
每周股票复盘:百克生物(688276)前三季度净亏损1.58亿元
股市必读:百克生物(688276)11月6日披露最新机构调研信息
证券之星 · 11-07
股市必读:百克生物(688276)11月6日披露最新机构调研信息
百克生物:中信证券、投资者等多家机构于11月5日调研我司
证券之星 · 11-06
百克生物:中信证券、投资者等多家机构于11月5日调研我司
每周股票复盘:百克生物(688276)Q3净利降179.31%
证券之星 · 11-02
每周股票复盘:百克生物(688276)Q3净利降179.31%
百克生物(688276)2025年三季报简析:净利润同比下降164.76%,三费占比上升明显
证券之星 · 11-01
百克生物(688276)2025年三季报简析:净利润同比下降164.76%,三费占比上升明显
图解百克生物三季报:第三季度单季净利润同比下降179.31%
证券之星 · 10-30
图解百克生物三季报:第三季度单季净利润同比下降179.31%
百克生物(688276)9月30日股东户数1.08万户,较上期增加7.23%
证券之星 · 10-30
百克生物(688276)9月30日股东户数1.08万户,较上期增加7.23%
百克生物:职工代表董事、副总经理孙晩丰辞任
每日经济新闻 · 10-23
百克生物:职工代表董事、副总经理孙晩丰辞任
百克生物最新公告:三价流感病毒裂解疫苗(BK-01佐剂)临床试验申请获批准
证券之星 · 10-13
百克生物最新公告:三价流感病毒裂解疫苗(BK-01佐剂)临床试验申请获批准
一针难求?RSV来袭预防需求激增 企业加速抢占婴幼儿市场
滚动播报 · 10-12
一针难求?RSV来袭预防需求激增 企业加速抢占婴幼儿市场
百克生物(688276.SH):吸附无细胞百白破b型流感嗜血杆菌联合疫苗临床试验申请获批
智通财经 · 10-09
百克生物(688276.SH):吸附无细胞百白破b型流感嗜血杆菌联合疫苗临床试验申请获批
百克生物:重组人源抗呼吸道合胞病毒单克隆抗体注射液项目处于临床前研究阶段
证券日报 · 09-26
百克生物:重组人源抗呼吸道合胞病毒单克隆抗体注射液项目处于临床前研究阶段
每周股票复盘:百克生物(688276)取消监事会并修订章程
证券之星 · 09-21
每周股票复盘:百克生物(688276)取消监事会并修订章程
每周股票复盘:百克生物(688276)带状疱疹疫苗销售下滑致业绩承压
证券之星 · 09-14
每周股票复盘:百克生物(688276)带状疱疹疫苗销售下滑致业绩承压
每周股票复盘:百克生物(688276)H1净亏损7357万
证券之星 · 09-07
每周股票复盘:百克生物(688276)H1净亏损7357万
加载更多
公司概况
公司名称:
长春百克生物科技股份公司
所属行业:
医药制造业
上市日期:
2021-06-25
主营业务:
长春百克生物科技股份公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是水痘疫苗、鼻喷流感疫苗、带状疱疹疫苗、液体鼻喷流感疫苗等。公司被吉林省科技厅认定为高新技术企业,批准设立“吉林省疫苗科技创新中心”、被吉林省发改委批准设立“吉林省疫苗工程研究中心”、被长春国家生物产业基地认定为“长春国家生物产业基地疫苗工程研究中心”、被吉林省工信厅认定为“省级企业技术中心”。
发行价格:
36.35
{"stockData":{"symbol":"688276","market":"SH","secType":"STK","nameCN":"百克生物","latestPrice":20.98,"timestamp":1764918001000,"preClose":20.95,"halted":0,"volume":2432507,"delay":0,"changeRate":0.0014,"floatShares":413999999,"shares":413999999,"eps":-0.4123,"marketStatus":"已收盘","change":0.03,"latestTime":"12-05 15:00:01","open":20.89,"high":21.03,"low":20.6,"amount":50631500,"amplitude":0.0205,"askPrice":21,"askSize":26,"bidPrice":20.98,"bidSize":25,"shortable":0,"etf":0,"ttmEps":-0.4123,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":20.95,"symbolType":"stock_kcb","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":23.05,"lowLimit":18.86,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":413657598,"isCdr":false,"pbRate":2.19,"roa":"--","roe":"--","epsLYR":0.56,"committee":-0.712538,"marketValue":8679000000,"turnoverRate":0.0059,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2025-12-08。","afterMarket":{"amount":0,"volume":0,"close":20.98,"buyVolume":0,"sellVolume":0,"time":1764920037768,"indexStatus":"已收盘 12-05 15:30:00","preClose":20.95},"floatMarketCap":8679000000},"requestUrl":"/m/hq/s/688276","defaultTab":"news","newsList":[{"id":"2585540594","title":"生长激素难助业绩长高!昔日“东北药茅”欲借港股翻盘?","url":"https://stock-news.laohu8.com/highlight/detail?id=2585540594","media":"投资时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585540594?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:21","pubTimestamp":1763972460,"startTime":"0","endTime":"0","summary":"编者按:拆解企业招股、估值、上市表现,以专业视角记录资本脉动。投资时间网携手标点财经联袂锻造“解码港股IPO”特别策划,深度探寻每一次资本浪潮背后的机遇与逻辑,敬请关注。投资时间 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20251124/c672688967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["000661","BK0188","BK0046","BK0028","BK0239","688276","BK0057","BK0075"],"gpt_icon":0},{"id":"2585190820","title":"11月21日百克生物跌5.81%,金鹰鑫瑞混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585190820","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585190820?lang=zh_cn&edition=full","pubTime":"2025-11-21 15:45","pubTimestamp":1763711153,"startTime":"0","endTime":"0","summary":"证券之星消息,11月21日百克生物跌5.81%创60日新低,收盘报21.06元,换手率1.55%,成交量6.42万手,成交额1.38亿元。重仓百克生物的公募基金请见下表:根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为金鹰基金的金鹰鑫瑞混合A。金鹰鑫瑞混合A目前规模为0.58亿元,最新净值1.3043,较上一交易日下跌0.07%,近一年上涨3.2%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100018690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2583654689","title":"每周股票复盘:百克生物(688276)成人百白破疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2583654689","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583654689?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:35","pubTimestamp":1763238912,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总:百克生物吸附无细胞百白破联合疫苗获临床试验批准。目前国内尚无针对青少年及成人的百白破疫苗获批。长春百克生物科技股份公司于2025年11月14日召开职工代表大会,选举佟雪莲女士为第六届董事会职工代表董事,任期至第六届董事会任期届满。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","688276"],"gpt_icon":0},{"id":"2583507878","title":"百克生物(688276)披露选举第六届董事会职工代表董事,11月14日股价上涨1.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583507878","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583507878?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:55","pubTimestamp":1763132119,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,百克生物报收于23.77元,较前一交易日上涨1.93%,最新总市值为98.33亿元。公司近日发布公告称,长春百克生物科技股份公司于2025年11月14日召开职工代表大会,选举佟雪莲女士为第六届董事会职工代表董事,任期至第六届董事会任期届满。本次选举后,兼任高管及职工代表董事人数未超过董事总数的二分之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2582283323","title":"百克生物(688276.SH):吸附无细胞百(二组分)白破联合疫苗(成人及青少年用)临床试验申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2582283323","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582283323?lang=zh_cn&edition=full","pubTime":"2025-11-12 15:38","pubTimestamp":1762933123,"startTime":"0","endTime":"0","summary":"智通财经APP讯, 百克生物(688276.SH)发布公告,公司近日收到国家药品监督管理局下发的吸附无细胞百(二组分)白破联合疫苗(成人及青少年用)的《药物临床试验批准通知书》。本次公司获批临床的吸附无细胞百(二组分)白破联合疫苗(成人及青少年用)(以下简称“青少年及成人百白破疫苗”)是一种可以同时预防青少年及成人百日咳、白喉、破伤风的疫苗。接种对象为10周岁及以上人群,接种后可刺激机体产生免疫应答,用于预防百日咳、白喉、破伤风引起的侵袭性感染。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百克生物(688276.SH):吸附无细胞百(二组分)白破联合疫苗(成人及青少年用)临床试验申请获得批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2582861605","title":"每周股票复盘:百克生物(688276)前三季度净亏损1.58亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582861605","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582861605?lang=zh_cn&edition=full","pubTime":"2025-11-09 03:49","pubTimestamp":1762631351,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,百克生物报收于21.79元,较上周的21.88元下跌0.41%。本周,百克生物11月4日盘中最高价报22.35元。研发投入17,789.79万元,占营收比例37.50%。带状疱疹疫苗销量同比减少,部分因前期确认收入的疫苗到期未接种而退货;同时公司开展惠民活动,以3-8折价格促销,导致单价下降、收入减少。Hib疫苗、重组带状疱疹疫苗、佐剂流感疫苗(四价)等5项临床试验申请获批,其中4项已取得批件;青少年及成人百白破疫苗已提交IND。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2581015241","title":"股市必读:百克生物(688276)11月6日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2581015241","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581015241?lang=zh_cn&edition=full","pubTime":"2025-11-07 01:43","pubTimestamp":1762450989,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘,百克生物报收于21.85元,下跌1.22%,换手率0.55%,成交量2.26万手,成交额4963.27万元。带状疱疹减毒活疫苗报告期内,带状疱疹疫苗同比销量减少、收入下降。报告期内,公司获得1项液体剂型鼻喷流感减毒活疫苗的生产批件;2款在研疫苗启动I期临床试验;申请佐剂流感疫苗等临床批件5项,其中4项已经取得临床批件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700001069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2581050372","title":"百克生物:中信证券、投资者等多家机构于11月5日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2581050372","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581050372?lang=zh_cn&edition=full","pubTime":"2025-11-06 17:33","pubTimestamp":1762421618,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年11月6日百克生物发布公告称中信证券李文涛、投资者于2025年11月5日调研我司。2025年前三季度,公司研发投入17,789.79万元,占营业收入37.50%;上年同期研发投入为11,650.33万元,占营业收入比例为11.35%。报告期内,公司获得1项液体剂型鼻喷流感减毒活疫苗的生产批件;2款在研疫苗启动I期临床试验;申请佐剂流感疫苗等临床批件5项,其中4项已经取得临床批件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600027577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK1521","600030","06030","LU1064130708.USD","BK1516","LU2289578879.USD","BK0196","LU1255011170.USD","LU2495084118.USD","LU1997245094.SGD","BK0028","BK0239","LU2148510915.USD","688276","LU1328615791.USD","LU1655091616.SGD","LU0405327494.USD","BK0188","LU1997244956.HKD","LU1720050803.USD","BK0012","BK1564","LU0405327148.USD","BK0276","LU1794554557.SGD","LU1997245177.USD","BK1147","BK0183"],"gpt_icon":0},{"id":"2580477816","title":"每周股票复盘:百克生物(688276)Q3净利降179.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580477816","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580477816?lang=zh_cn&edition=full","pubTime":"2025-11-02 07:03","pubTimestamp":1762038199,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,百克生物报收于21.88元,较上周的22.03元下跌0.68%。本周,百克生物10月27日盘中最高价报22.18元。业绩披露要点百克生物2025年三季报显示,前三季度主营收入4.74亿元,同比下降53.76%;归母净利润-1.58亿元,同比下降164.76%;扣非净利润-1.8亿元,同比下降173.4%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2580173914","title":"百克生物(688276)2025年三季报简析:净利润同比下降164.76%,三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2580173914","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580173914?lang=zh_cn&edition=full","pubTime":"2025-11-01 06:49","pubTimestamp":1761950991,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期百克生物发布2025年三季报。截至本报告期末,公司营业总收入4.74亿元,同比下降53.76%,归母净利润-1.58亿元,同比下降164.76%。本报告期百克生物三费占比上升明显,财务费用、销售费用和管理费用总和占总营收同比增幅达74.01%。受外部环境、市场竞争加剧以及受种者疫苗接种意愿下降等多方面因素的影响,公司带状疱疹疫苗销售、使用数量大幅减少,销售收入承压,对公司整体营业收入、净利润造成影响,收入、利润同比下降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100007890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276"],"gpt_icon":0},{"id":"2579498781","title":"图解百克生物三季报:第三季度单季净利润同比下降179.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579498781","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579498781?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:09","pubTimestamp":1761826159,"startTime":"0","endTime":"0","summary":"证券之星消息,百克生物2025年三季报显示,前三季度公司主营收入4.74亿元,同比下降53.76%;归母净利润-1.58亿元,同比下降164.76%;扣非净利润-1.8亿元,同比下降173.4%;其中2025年第三季度,公司单季度主营收入1.9亿元,同比下降53.5%;单季度归母净利润-8467.71万元,同比下降179.31%;单季度扣非净利润-9749.43万元,同比下降188.98%;负债率24.04%,投资收益-2457.28万元,财务费用120.89万元,毛利率75.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000040787.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276"],"gpt_icon":0},{"id":"2579118934","title":"百克生物(688276)9月30日股东户数1.08万户,较上期增加7.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579118934","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579118934?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:28","pubTimestamp":1761816531,"startTime":"0","endTime":"0","summary":"户均持股数量由上期的4.1万股减少至3.82万股,户均持股市值为83.77万元。在生物制品行业个股中,百克生物股东户数低于行业平均水平,截至9月30日,生物制品行业平均股东户数为3.41万户。从股价来看,2025年6月30日至2025年9月30日,百克生物区间涨幅为4.38%,在此期间股东户数增加730.0户,增幅为7.23%。根据统计,百克生物2025年6月30日至2025年9月30日,主力资金净流出2.6亿元,游资资金净流入1.38亿元,散户资金净流入1.22亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000033161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2577260305","title":"百克生物:职工代表董事、副总经理孙晩丰辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2577260305","media":"每日经济新闻","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577260305?lang=zh_cn&edition=full","pubTime":"2025-10-23 19:00","pubTimestamp":1761217200,"startTime":"0","endTime":"0","summary":"每经AI快讯,10月23日,百克生物公告,孙晩丰先生因工作调整,辞去公司第六届董事会职工代表董事、副总经理职务,离任后仍担任董事长助理。公司将在法定程序下尽快完成职工代表董事的补选工作。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-23/doc-infuwsqk9351644.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-23/doc-infuwsqk9351644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2575711184","title":"百克生物最新公告:三价流感病毒裂解疫苗(BK-01佐剂)临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2575711184","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575711184?lang=zh_cn&edition=full","pubTime":"2025-10-13 17:31","pubTimestamp":1760347876,"startTime":"0","endTime":"0","summary":"百克生物(688276.SH)公告称,公司近日收到国家药品监督管理局下发的三价流感病毒裂解疫苗(BK-01佐剂)的《药物临床试验批准通知书》。该疫苗接种对象为60岁及以上人群。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300020365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","688276"],"gpt_icon":0},{"id":"2574461129","title":"一针难求?RSV来袭预防需求激增 企业加速抢占婴幼儿市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2574461129","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574461129?lang=zh_cn&edition=full","pubTime":"2025-10-12 00:25","pubTimestamp":1760199900,"startTime":"0","endTime":"0","summary":"据中国疾控中心10月9日发布的今年第40周全国急性呼吸道传染病哨点监测数据显示,RSV在哨点医院门急诊流感样病例、住院严重急性呼吸道感染病例的呼吸道样本检测阳性率中,均位列第二。 在RSV持续高发的背景下,其预防与治疗的市场想象空间不断被放大,一场聚焦该赛道的药物研发竞速赛正拉开帷幕,尽显百舸争流之态。 截至目前,全球尚无专门靶向RSV的特效药获批,现有干预以对症治疗为主。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-12/doc-inftpzyh5284825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","02257","BK0046","01672","06660","LU2148510915.USD","BK0188","LU1328615791.USD","BK0077","BK1161","BK0239","BK0070","LU2580892862.HKD","688443","BK0196","BK1515","LU2580892789.USD","159982","300122","LU1064131003.USD","LU1064130708.USD","688276","300142"],"gpt_icon":0},{"id":"2574136679","title":"百克生物(688276.SH):吸附无细胞百白破b型流感嗜血杆菌联合疫苗临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2574136679","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574136679?lang=zh_cn&edition=full","pubTime":"2025-10-09 15:40","pubTimestamp":1759995625,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百克生物 发布公告,公司近日收到国家药品监督管理局下发的吸附无细胞百白破b型流感嗜血杆菌联合疫苗的《药物临床试验批准通知书》。本次公司获批临床的吸附无细胞百白破b型流感嗜血杆菌联合疫苗是一种可以同时预防百日咳、白喉、破伤风以及b型流感嗜血杆菌的疫苗。接种对象为2月龄及以上婴幼儿,接种后可刺激机体产生免疫应答,用于预防百日咳、白喉、破伤风和b型流感嗜血杆菌引起的侵袭性感染。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1353047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百克生物(688276.SH):吸附无细胞百白破b型流感嗜血杆菌联合疫苗临床试验申请获批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2570861648","title":"百克生物:重组人源抗呼吸道合胞病毒单克隆抗体注射液项目处于临床前研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2570861648","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570861648?lang=zh_cn&edition=full","pubTime":"2025-09-26 20:09","pubTimestamp":1758888540,"startTime":"0","endTime":"0","summary":"证券日报网讯百克生物9月26日在互动平台回答投资者提问时表示,公司在研项目中包含重组人源抗呼吸道合胞病毒单克隆抗体注射液项目,目前处于临床前研究阶段。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-26/doc-infrvstk0471178.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-26/doc-infrvstk0471178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2569246456","title":"每周股票复盘:百克生物(688276)取消监事会并修订章程","url":"https://stock-news.laohu8.com/highlight/detail?id=2569246456","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569246456?lang=zh_cn&edition=full","pubTime":"2025-09-21 04:38","pubTimestamp":1758400692,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘,百克生物报收于22.05元,较上周的22.93元下跌3.84%。本周关注点公司公告汇总:百克生物股东大会通过取消监事会、修订公司章程的议案。长春百克生物科技股份公司于2025年9月16日召开2025年第二次临时股东会,会议审议通过上述两项议案。长春百克生物科技股份公司于2025年9月16日召开职工代表大会,选举孙晚丰先生为公司第六届董事会职工代表董事,任期至第六届董事会任期届满。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100001161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2567367661","title":"每周股票复盘:百克生物(688276)带状疱疹疫苗销售下滑致业绩承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2567367661","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567367661?lang=zh_cn&edition=full","pubTime":"2025-09-14 05:19","pubTimestamp":1757798354,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘,百克生物报收于22.93元,较上周的22.98元下跌0.22%。机构调研要点2025年上半年,我国疫苗行业面临多方面挑战,肺炎疫苗、带状疱疹疫苗、流感疫苗等多款非免疫规划疫苗批签发批次同比下降,部分产品下降超50%。受外部环境、市场竞争加剧及接种意愿下降等因素影响,公司带状疱疹疫苗销售与使用数量大幅减少,销售收入承压,导致整体营业收入与净利润同比下降。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400001277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159646","688276"],"gpt_icon":0},{"id":"2565548081","title":"每周股票复盘:百克生物(688276)H1净亏损7357万","url":"https://stock-news.laohu8.com/highlight/detail?id=2565548081","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565548081?lang=zh_cn&edition=full","pubTime":"2025-09-07 04:19","pubTimestamp":1757189950,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘,百克生物报收于22.98元,较上周的23.9元下跌3.85%。本周关注点业绩披露要点:2025年上半年公司净亏损7,357.34万元,同比下滑153.47%。带状疱疹疫苗全国城市覆盖率约98%,区县覆盖率约86%,安全库存合理;截至6月30日,全国近600家医院实现新准入。公司下半年将保持水痘疫苗领先地位,深耕带状疱疹疫苗与流感疫苗销售,推动医防融合新模式;液体鼻喷流感疫苗预计年底获批签发,争取实现销售;研发工作聚焦临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090700000837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765055124577,"stockEarnings":[{"period":"1week","weight":-0.0269},{"period":"1month","weight":-0.0515},{"period":"3month","weight":-0.087},{"period":"6month","weight":0.0022},{"period":"1year","weight":-0.2115},{"period":"ytd","weight":-0.1578}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春百克生物科技股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10824人(较上一季度增加7.23%)","perCapita":"38216股","listingDate":"2021-06-25","address":"吉林省长春市朝阳区高新开发区火炬路1260号","registeredCapital":"41365万元","survey":" 长春百克生物科技股份公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是水痘疫苗、鼻喷流感疫苗、带状疱疹疫苗、液体鼻喷流感疫苗等。公司被吉林省科技厅认定为高新技术企业,批准设立“吉林省疫苗科技创新中心”、被吉林省发改委批准设立“吉林省疫苗工程研究中心”、被长春国家生物产业基地认定为“长春国家生物产业基地疫苗工程研究中心”、被吉林省工信厅认定为“省级企业技术中心”。","listedPrice":36.35},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百克生物(688276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百克生物(688276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百克生物,688276,百克生物股票,百克生物股票老虎,百克生物股票老虎国际,百克生物行情,百克生物股票行情,百克生物股价,百克生物股市,百克生物股票价格,百克生物股票交易,百克生物股票购买,百克生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百克生物(688276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百克生物(688276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}